about
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.Incidental parenchymal magnetic resonance imaging findings in the brains of patients with neurofibromatosis type 2.Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological functionEfficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models.The life span of new neurons in a song control nucleus of the adult canary brain depends on time of year when these cells are bornThe genetic and molecular pathogenesis of NF1 and NF2.Vascular distribution of glioblastoma multiforme at diagnosisAssessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging.Brain Region-Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease).Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.Neurofibromatosis type 1 and associated malignancies.Orthopaedic aspects of neurofibromatosis: update.A neurologic presentation of familial hemophagocytic lymphohistiocytosis which mimicked septic emboli to the brain.Inverse correlation between cerebral blood flow measured by continuous arterial spin-labeling (CASL) MRI and neurocognitive function in children with sickle cell anemia (SCA).Neuro-behçet disease in an african american adolescent.Ophthalmic artery ischemic syndrome associated with neurofibromatosis and moyamoya syndrome.Panuveitis in association with pseudotumor cerebri.Offense produced by chemical stimulation of the anterior hypothalamus of the rat.Song-selective auditory input to a forebrain vocal control nucleus in the zebra finch.Practice parameter: evaluation of the child with global developmental delay.Creation of an international registry to support discovery in schwannomatosis.Response to Hannah-Shmouni and StratakisAccuracy of Reported Community Diagnosis of Autism Spectrum DisorderDisease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort studyComparison of hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities
P50
Q30406342-564531B5-B9B9-44DA-A3CA-AFBE38C1EAF8Q30443355-255F018B-2D69-496F-B872-15E802EE7C59Q34981680-7BFA73ED-8D6F-4031-9BC1-560CF30F6065Q35067815-CAF78786-7F7A-486A-A79B-DEEE3A922DE4Q35668456-13F88F6B-7908-4137-A3AB-9D78E13D4E95Q36526233-FFF09FBD-F72D-4DAB-87D7-F5C69909B42EQ36696392-B60C636E-E773-4261-9BF1-05A0675EE8C6Q36817967-80922B4C-BBD2-4C8F-AADC-52C9B4C611CAQ37004315-C2627E36-C9EA-4718-A3A6-9026225A9B74Q37358381-E0617C8D-6C17-49F7-AF33-6D76EEEB1E34Q37434668-133CA2BB-4E3F-43B5-A112-9C29155B2540Q37819881-32868D56-CB46-4896-A3FB-AA5364FBADB8Q40441236-8AEFDECD-B5A5-4710-9A34-4B1A522AA06DQ41676000-A064CC7B-C93E-4772-9C33-97051B4F4795Q42136218-636BB5E7-A72D-4BBE-AB0A-F5C81FAEFC92Q44950325-FA3E76E8-E8AD-4CD2-AE65-6CDBBA293502Q46439320-BB9CBEE2-0D34-45F7-84B8-9B76B53B7F79Q48271998-61BBA73D-33CA-4619-A806-30897FB63588Q48305748-9B3464F4-F6ED-42C7-802A-65A2ACB56747Q52096487-8B756068-001E-467F-A16B-93A450B58304Q53035106-712E5566-9574-43DC-88B1-230A9A05E108Q57026987-5AEA84FC-85E7-4FFE-930B-E89797097FB3Q57126794-BA6AACB9-C6D9-4875-A041-0710CE8A1BECQ57173036-E6900A60-F5B1-4747-845D-DF3A091E20BEQ90039864-DF56387D-A136-4C6B-99E4-B94E3D48EB21Q90129581-32FD575E-5241-4BBC-BD41-CAE286A7C24CQ90602456-60A329D1-EC0B-4B5C-B230-CBA499EE6070Q91775221-1824D8EA-1F9D-4D11-8771-390C8C05B320
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kaleb Yohay
@ast
Kaleb Yohay
@en
Kaleb Yohay
@es
Kaleb Yohay
@nl
Kaleb Yohay
@sl
type
label
Kaleb Yohay
@ast
Kaleb Yohay
@en
Kaleb Yohay
@es
Kaleb Yohay
@nl
Kaleb Yohay
@sl
prefLabel
Kaleb Yohay
@ast
Kaleb Yohay
@en
Kaleb Yohay
@es
Kaleb Yohay
@nl
Kaleb Yohay
@sl
P106
P21
P31
P496
0000-0001-5560-3392
P569
2000-01-01T00:00:00Z